Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
Laila Shalabi, Medical Student at Gharyan Central Hospital, Libya, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“Adding a voice to an ongoing clinical debate. While recent meta-analyses favor clopidogrel over aspirin, the nuances of concomitant medications specifically Proton Pump Inhibitors (PPIs) cannot be ignored.
In our Lancet correspondence, we highlighted that while clopidogrel is superior to aspirin, concurrent PPI use significantly attenuates its bleeding and efficacy benefits, making a patient’s medication list a primary determinant of clinical success. We specifically recommended pantoprazole for its better pharmacodynamic profile and called for more targeted research. The authors replied by acknowledging that while PPIs might modify bleeding risk, clopidogrel’s ischemic benefits remain consistent and superior regardless of PPI use.
They further cautioned against overinterpreting subgroup trends where no significant treatment-by-subgroup interaction was observed for cardiovascular outcomes. This dialogue underscores the clinical complexity of antiplatelet therapy in the secondary prevention phase.
I am deeply grateful to my colleague Ahmed Ibrahim for the true teamwork, and to our mentor Prof.Andò for his continuous support and guidance.”
Title: Clopidogrel versus aspirin for coronary artery disease
Authors: Ahmed Ibrahim, Laila Shalabi, Giuseppe Andó
Read the Full Article on The Lancet.

Title: Clopidogrel versus aspirin for coronary artery disease – Authors’ reply
Authors: Marco Valgimiglia, Felice Gragnano, Daniele Giacoppo
Read the Author’s Reply on The Lancet.

Stay updated on all scientific advances with Hemostasis Today.
-
Apr 22, 2026, 07:56Shruti Kharat: Closing the Gap in Early Detection of Factor VIII Inhibitors
-
Apr 22, 2026, 07:46Gregory Piazza: Ushering in a New Era in PE Therapy and Improved Clinical Outcomes for Our Patients
-
Apr 22, 2026, 07:40Akshat Jain: WIL33 Study Advances Factor Prophylaxis in Children with von Willebrand Disease
-
Apr 22, 2026, 07:36Selma Turkovic: Blood Transfusion Education and Discussion Group Webinar 61
-
Apr 22, 2026, 07:34Aikati Anastasiou: Advancing Stroke Imaging Insights from the DISTAL Trial
-
Apr 22, 2026, 07:26Maxime Dely: How Do We Balance Benefit and Risk in Chronic Hematologic Diseases?
-
Apr 22, 2026, 07:19Sarah Richardson: Bringing Insights from HFA Symposium Back to Real Life
-
Apr 22, 2026, 07:17Karuna Kumar: Interesting Trial from Gambia on Treating Iron Deficiency in Children
-
Apr 22, 2026, 07:12Mary Catherine Moffett: Celebrating 32 Years of Patient-Centered Advocacy with the Hemophilia Federation of America